Bio-Rad Laboratories, Inc. (BIO-B) Stock Competitors & Peer Comparison
See (BIO-B) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO-B | $321.48 | +5.70% | 8.7B | 53.40 | $6.02 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $91.04 | +4.66% | 158B | 25.41 | $3.57 | +2.71% |
| ISRG | $420.35 | +3.21% | 148.4B | 50.78 | $8.25 | N/A |
| SYK | $303.93 | +3.03% | 115.4B | 34.81 | $8.65 | +1.15% |
| MDT | $81.18 | +4.14% | 105.2B | 21.97 | $3.73 | +3.49% |
| BSX | $48.45 | +1.59% | 72.6B | 20.43 | $2.39 | N/A |
| BRKRP | $422.62 | -8.84% | 67.4B | N/A | N/A | +0.33% |
| EW | $84.82 | -1.38% | 50.3B | 47.26 | $1.85 | N/A |
| RMD | $195.34 | +4.76% | 28.2B | 18.74 | $10.37 | +1.25% |
Stock Comparison
BIO-B vs BSX-PA Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIO-B is priced at $321.48, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIO-B's ROE is +0.02%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSX-PA's competition here
BIO-B vs ABT Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ABT has a market cap of 158B. Regarding current trading prices, BIO-B is priced at $321.48, while ABT trades at $91.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ABT's P/E ratio is 25.41. In terms of profitability, BIO-B's ROE is +0.02%, compared to ABT's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ABT's competition here
BIO-B vs ISRG Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ISRG has a market cap of 148.4B. Regarding current trading prices, BIO-B is priced at $321.48, while ISRG trades at $420.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ISRG's P/E ratio is 50.78. In terms of profitability, BIO-B's ROE is +0.02%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, BIO-B is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ISRG's competition here
BIO-B vs SYK Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SYK has a market cap of 115.4B. Regarding current trading prices, BIO-B is priced at $321.48, while SYK trades at $303.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SYK's P/E ratio is 34.81. In terms of profitability, BIO-B's ROE is +0.02%, compared to SYK's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SYK's competition here
BIO-B vs MDT Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, MDT has a market cap of 105.2B. Regarding current trading prices, BIO-B is priced at $321.48, while MDT trades at $81.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas MDT's P/E ratio is 21.97. In terms of profitability, BIO-B's ROE is +0.02%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MDT's competition here
BIO-B vs BSX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BSX has a market cap of 72.6B. Regarding current trading prices, BIO-B is priced at $321.48, while BSX trades at $48.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BSX's P/E ratio is 20.43. In terms of profitability, BIO-B's ROE is +0.02%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSX's competition here
BIO-B vs BRKRP Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BRKRP has a market cap of 67.4B. Regarding current trading prices, BIO-B is priced at $321.48, while BRKRP trades at $422.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BRKRP's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.02%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, BIO-B is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BRKRP's competition here
BIO-B vs EW Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, EW has a market cap of 50.3B. Regarding current trading prices, BIO-B is priced at $321.48, while EW trades at $84.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas EW's P/E ratio is 47.26. In terms of profitability, BIO-B's ROE is +0.02%, compared to EW's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check EW's competition here
BIO-B vs RMD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, RMD has a market cap of 28.2B. Regarding current trading prices, BIO-B is priced at $321.48, while RMD trades at $195.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas RMD's P/E ratio is 18.74. In terms of profitability, BIO-B's ROE is +0.02%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BIO-B is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check RMD's competition here
BIO-B vs DXCM Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, DXCM has a market cap of 28B. Regarding current trading prices, BIO-B is priced at $321.48, while DXCM trades at $72.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas DXCM's P/E ratio is 31.15. In terms of profitability, BIO-B's ROE is +0.02%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, BIO-B is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check DXCM's competition here
BIO-B vs PHG Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, PHG has a market cap of 25.3B. Regarding current trading prices, BIO-B is priced at $321.48, while PHG trades at $26.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas PHG's P/E ratio is 22.40. In terms of profitability, BIO-B's ROE is +0.02%, compared to PHG's ROE of +0.09%. Regarding short-term risk, BIO-B is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PHG's competition here
BIO-B vs STE Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, STE has a market cap of 20.7B. Regarding current trading prices, BIO-B is priced at $321.48, while STE trades at $211.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas STE's P/E ratio is 26.76. In terms of profitability, BIO-B's ROE is +0.02%, compared to STE's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check STE's competition here
BIO-B vs ABMD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIO-B is priced at $321.48, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIO-B's ROE is +0.02%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIO-B is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check ABMD's competition here
BIO-B vs ZBH Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ZBH has a market cap of 16.8B. Regarding current trading prices, BIO-B is priced at $321.48, while ZBH trades at $86.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ZBH's P/E ratio is 22.46. In terms of profitability, BIO-B's ROE is +0.02%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BIO-B is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ZBH's competition here
BIO-B vs SNN Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, BIO-B is priced at $321.48, while SNN trades at $30.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SNN's P/E ratio is 21.57. In terms of profitability, BIO-B's ROE is +0.02%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SNN's competition here
BIO-B vs PEN Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, BIO-B is priced at $321.48, while PEN trades at $320.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas PEN's P/E ratio is 74.06. In terms of profitability, BIO-B's ROE is +0.02%, compared to PEN's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PEN's competition here
BIO-B vs SWAV Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIO-B is priced at $321.48, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIO-B's ROE is +0.02%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BIO-B is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check SWAV's competition here
BIO-B vs ALGN Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ALGN has a market cap of 12.1B. Regarding current trading prices, BIO-B is priced at $321.48, while ALGN trades at $166.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ALGN's P/E ratio is 28.33. In terms of profitability, BIO-B's ROE is +0.02%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ALGN's competition here
BIO-B vs GMED Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, BIO-B is priced at $321.48, while GMED trades at $80.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas GMED's P/E ratio is 18.69. In terms of profitability, BIO-B's ROE is +0.02%, compared to GMED's ROE of +0.13%. Regarding short-term risk, BIO-B is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check GMED's competition here
BIO-B vs PODD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, BIO-B is priced at $321.48, while PODD trades at $152.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas PODD's P/E ratio is 34.29. In terms of profitability, BIO-B's ROE is +0.02%, compared to PODD's ROE of +0.21%. Regarding short-term risk, BIO-B is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PODD's competition here
BIO-B vs MASI Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BIO-B is priced at $321.48, while MASI trades at $178.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas MASI's P/E ratio is 44.28. In terms of profitability, BIO-B's ROE is +0.02%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BIO-B is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check MASI's competition here
BIO-B vs BRKR Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, BIO-B is priced at $321.48, while BRKR trades at $56.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BRKR's P/E ratio is -249.83. In terms of profitability, BIO-B's ROE is +0.02%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, BIO-B is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BRKR's competition here
BIO-B vs BIO Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BIO has a market cap of 8.3B. Regarding current trading prices, BIO-B is priced at $321.48, while BIO trades at $291.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BIO's P/E ratio is 51.06. In terms of profitability, BIO-B's ROE is +0.02%, compared to BIO's ROE of +0.02%. Regarding short-term risk, BIO-B is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BIO's competition here
BIO-B vs GKOS Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, BIO-B is priced at $321.48, while GKOS trades at $124.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas GKOS's P/E ratio is -36.87. In terms of profitability, BIO-B's ROE is +0.02%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, BIO-B is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check GKOS's competition here
BIO-B vs NARI Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIO-B is priced at $321.48, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIO-B's ROE is +0.02%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BIO-B is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check NARI's competition here
BIO-B vs LIVN Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, BIO-B is priced at $321.48, while LIVN trades at $72.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas LIVN's P/E ratio is 37.61. In terms of profitability, BIO-B's ROE is +0.02%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, BIO-B is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LIVN's competition here
BIO-B vs AXNX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BIO-B is priced at $321.48, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BIO-B's ROE is +0.02%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BIO-B is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check AXNX's competition here
BIO-B vs IRTC Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, BIO-B is priced at $321.48, while IRTC trades at $107.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas IRTC's P/E ratio is -126.29. In terms of profitability, BIO-B's ROE is +0.02%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, BIO-B is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IRTC's competition here
BIO-B vs ITGR Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, BIO-B is priced at $321.48, while ITGR trades at $92.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ITGR's P/E ratio is 23.01. In terms of profitability, BIO-B's ROE is +0.02%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, BIO-B is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ITGR's competition here
BIO-B vs TMDX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, BIO-B is priced at $321.48, while TMDX trades at $69.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas TMDX's P/E ratio is 16.33. In terms of profitability, BIO-B's ROE is +0.02%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, BIO-B is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TMDX's competition here
BIO-B vs AXGN Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, BIO-B is priced at $321.48, while AXGN trades at $42.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas AXGN's P/E ratio is -66.23. In terms of profitability, BIO-B's ROE is +0.02%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, BIO-B is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AXGN's competition here
BIO-B vs ESTA Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, BIO-B is priced at $321.48, while ESTA trades at $74.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ESTA's P/E ratio is -52.03. In terms of profitability, BIO-B's ROE is +0.02%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, BIO-B is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ESTA's competition here
BIO-B vs NUVA Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIO-B is priced at $321.48, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIO-B's ROE is +0.02%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NUVA's competition here
BIO-B vs UFPT Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, BIO-B is priced at $321.48, while UFPT trades at $222.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas UFPT's P/E ratio is 25.54. In terms of profitability, BIO-B's ROE is +0.02%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BIO-B is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check UFPT's competition here
BIO-B vs PRCT Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, BIO-B is priced at $321.48, while PRCT trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas PRCT's P/E ratio is -14.75. In terms of profitability, BIO-B's ROE is +0.02%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, BIO-B is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PRCT's competition here
BIO-B vs IART Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, BIO-B is priced at $321.48, while IART trades at $16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas IART's P/E ratio is -2.71. In terms of profitability, BIO-B's ROE is +0.02%, compared to IART's ROE of -0.48%. Regarding short-term risk, BIO-B is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IART's competition here
BIO-B vs BFLY Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, BIO-B is priced at $321.48, while BFLY trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BFLY's P/E ratio is -17.30. In terms of profitability, BIO-B's ROE is +0.02%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, BIO-B is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BFLY's competition here
BIO-B vs TNDM Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $321.48, while TNDM trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas TNDM's P/E ratio is -14.19. In terms of profitability, BIO-B's ROE is +0.02%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, BIO-B is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TNDM's competition here
BIO-B vs AHCO Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $321.48, while AHCO trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas AHCO's P/E ratio is -16.47. In terms of profitability, BIO-B's ROE is +0.02%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, BIO-B is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AHCO's competition here
BIO-B vs ENOV Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $321.48, while ENOV trades at $23.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ENOV's P/E ratio is -1.15. In terms of profitability, BIO-B's ROE is +0.02%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, BIO-B is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ENOV's competition here
BIO-B vs HSKA Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $321.48, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIO-B's ROE is +0.02%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIO-B is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check HSKA's competition here
BIO-B vs ATEC Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $321.48, while ATEC trades at $7.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ATEC's P/E ratio is -9.54. In terms of profitability, BIO-B's ROE is +0.02%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, BIO-B is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ATEC's competition here
BIO-B vs INSP Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $321.48, while INSP trades at $41.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas INSP's P/E ratio is 9.58. In terms of profitability, BIO-B's ROE is +0.02%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BIO-B is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check INSP's competition here
BIO-B vs IRMD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $321.48, while IRMD trades at $93.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas IRMD's P/E ratio is 51.13. In terms of profitability, BIO-B's ROE is +0.02%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, BIO-B is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IRMD's competition here
BIO-B vs AVNS Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $321.48, while AVNS trades at $25.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas AVNS's P/E ratio is -15.62. In terms of profitability, BIO-B's ROE is +0.02%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BIO-B and AVNS have similar daily volatility (0.48).Check AVNS's competition here
BIO-B vs SILK Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $321.48, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIO-B's ROE is +0.02%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BIO-B is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check SILK's competition here
BIO-B vs FNA Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $321.48, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIO-B's ROE is +0.02%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BIO-B is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check FNA's competition here
BIO-B vs CNMD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $321.48, while CNMD trades at $34.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CNMD's P/E ratio is 19.84. In terms of profitability, BIO-B's ROE is +0.02%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CNMD's competition here
BIO-B vs AORT Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, AORT has a market cap of 1B. Regarding current trading prices, BIO-B is priced at $321.48, while AORT trades at $20.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas AORT's P/E ratio is 83.32. In terms of profitability, BIO-B's ROE is +0.02%, compared to AORT's ROE of +0.03%. Regarding short-term risk, BIO-B is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AORT's competition here
BIO-B vs CSII Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIO-B is priced at $321.48, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIO-B's ROE is +0.02%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIO-B is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check CSII's competition here
BIO-B vs INMD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, INMD has a market cap of 828.2M. Regarding current trading prices, BIO-B is priced at $321.48, while INMD trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas INMD's P/E ratio is 10.09. In terms of profitability, BIO-B's ROE is +0.02%, compared to INMD's ROE of +0.13%. Regarding short-term risk, BIO-B is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check INMD's competition here
BIO-B vs LMRI Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, LMRI has a market cap of 791.7M. Regarding current trading prices, BIO-B is priced at $321.48, while LMRI trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas LMRI's P/E ratio is -21.13. In terms of profitability, BIO-B's ROE is +0.02%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, BIO-B is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LMRI's competition here
BIO-B vs SSII Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SSII has a market cap of 768.5M. Regarding current trading prices, BIO-B is priced at $321.48, while SSII trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SSII's P/E ratio is -76.80. In terms of profitability, BIO-B's ROE is +0.02%, compared to SSII's ROE of -0.23%. Regarding short-term risk, BIO-B is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SSII's competition here
BIO-B vs CRY Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, BIO-B is priced at $321.48, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CRY's P/E ratio is 425.71. In terms of profitability, BIO-B's ROE is +0.02%, compared to CRY's ROE of +0.03%. Regarding short-term risk, BIO-B is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CRY's competition here
BIO-B vs CBLL Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CBLL has a market cap of 711.4M. Regarding current trading prices, BIO-B is priced at $321.48, while CBLL trades at $18.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CBLL's P/E ratio is -11.57. In terms of profitability, BIO-B's ROE is +0.02%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, BIO-B is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CBLL's competition here
BIO-B vs SIBN Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SIBN has a market cap of 659.9M. Regarding current trading prices, BIO-B is priced at $321.48, while SIBN trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SIBN's P/E ratio is -38.15. In terms of profitability, BIO-B's ROE is +0.02%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, BIO-B is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SIBN's competition here
BIO-B vs SRDX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BIO-B is priced at $321.48, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BIO-B's ROE is +0.02%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, BIO-B is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check SRDX's competition here
BIO-B vs BVS Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BVS has a market cap of 589.4M. Regarding current trading prices, BIO-B is priced at $321.48, while BVS trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BVS's P/E ratio is 21.22. In terms of profitability, BIO-B's ROE is +0.02%, compared to BVS's ROE of +0.16%. Regarding short-term risk, BIO-B is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BVS's competition here
BIO-B vs APEN Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIO-B is priced at $321.48, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIO-B's ROE is +0.02%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIO-B is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check APEN's competition here
BIO-B vs TCMD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, TCMD has a market cap of 567.7M. Regarding current trading prices, BIO-B is priced at $321.48, while TCMD trades at $25.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas TCMD's P/E ratio is 28.93. In terms of profitability, BIO-B's ROE is +0.02%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TCMD's competition here
BIO-B vs BWAY Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BWAY has a market cap of 559.7M. Regarding current trading prices, BIO-B is priced at $321.48, while BWAY trades at $13.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BWAY's P/E ratio is 64.86. In terms of profitability, BIO-B's ROE is +0.02%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BWAY's competition here
BIO-B vs CTKB Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CTKB has a market cap of 559.2M. Regarding current trading prices, BIO-B is priced at $321.48, while CTKB trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CTKB's P/E ratio is -7.47. In terms of profitability, BIO-B's ROE is +0.02%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, BIO-B is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CTKB's competition here
BIO-B vs CERS Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CERS has a market cap of 559M. Regarding current trading prices, BIO-B is priced at $321.48, while CERS trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CERS's P/E ratio is -55.80. In terms of profitability, BIO-B's ROE is +0.02%, compared to CERS's ROE of -0.15%. Regarding short-term risk, BIO-B is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CERS's competition here
BIO-B vs NPCE Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, NPCE has a market cap of 556.4M. Regarding current trading prices, BIO-B is priced at $321.48, while NPCE trades at $15.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas NPCE's P/E ratio is -25.11. In terms of profitability, BIO-B's ROE is +0.02%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, BIO-B is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NPCE's competition here
BIO-B vs ZIMV Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BIO-B is priced at $321.48, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BIO-B's ROE is +0.02%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, BIO-B is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check ZIMV's competition here
BIO-B vs PACB Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, PACB has a market cap of 506.3M. Regarding current trading prices, BIO-B is priced at $321.48, while PACB trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas PACB's P/E ratio is -3.98. In terms of profitability, BIO-B's ROE is +0.02%, compared to PACB's ROE of -4.88%. Regarding short-term risk, BIO-B is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PACB's competition here
BIO-B vs PMI Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, PMI has a market cap of 498.9M. Regarding current trading prices, BIO-B is priced at $321.48, while PMI trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas PMI's P/E ratio is -0.42. In terms of profitability, BIO-B's ROE is +0.02%, compared to PMI's ROE of +4.99%. Regarding short-term risk, BIO-B is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PMI's competition here
BIO-B vs LAB Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, LAB has a market cap of 488M. Regarding current trading prices, BIO-B is priced at $321.48, while LAB trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas LAB's P/E ratio is -9.62. In terms of profitability, BIO-B's ROE is +0.02%, compared to LAB's ROE of -0.21%. Regarding short-term risk, BIO-B is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LAB's competition here
BIO-B vs KIDS Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, KIDS has a market cap of 464.9M. Regarding current trading prices, BIO-B is priced at $321.48, while KIDS trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas KIDS's P/E ratio is -10.77. In terms of profitability, BIO-B's ROE is +0.02%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, BIO-B is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check KIDS's competition here
BIO-B vs VREX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, VREX has a market cap of 440.4M. Regarding current trading prices, BIO-B is priced at $321.48, while VREX trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas VREX's P/E ratio is -5.23. In terms of profitability, BIO-B's ROE is +0.02%, compared to VREX's ROE of -0.18%. Regarding short-term risk, BIO-B is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check VREX's competition here
BIO-B vs CLPT Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CLPT has a market cap of 429.5M. Regarding current trading prices, BIO-B is priced at $321.48, while CLPT trades at $12.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CLPT's P/E ratio is -14.32. In terms of profitability, BIO-B's ROE is +0.02%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, BIO-B is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CLPT's competition here
BIO-B vs OFIX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, OFIX has a market cap of 416.7M. Regarding current trading prices, BIO-B is priced at $321.48, while OFIX trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas OFIX's P/E ratio is -6.87. In terms of profitability, BIO-B's ROE is +0.02%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, BIO-B is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check OFIX's competition here
BIO-B vs VMD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, VMD has a market cap of 377.2M. Regarding current trading prices, BIO-B is priced at $321.48, while VMD trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas VMD's P/E ratio is 26.59. In terms of profitability, BIO-B's ROE is +0.02%, compared to VMD's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check VMD's competition here
BIO-B vs DCTH Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, DCTH has a market cap of 372.5M. Regarding current trading prices, BIO-B is priced at $321.48, while DCTH trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas DCTH's P/E ratio is 1079.00. In terms of profitability, BIO-B's ROE is +0.02%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, BIO-B is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check DCTH's competition here
BIO-B vs AVR Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, AVR has a market cap of 355M. Regarding current trading prices, BIO-B is priced at $321.48, while AVR trades at $9.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas AVR's P/E ratio is -4.35. In terms of profitability, BIO-B's ROE is +0.02%, compared to AVR's ROE of -1.24%. Regarding short-term risk, BIO-B is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AVR's competition here
BIO-B vs ICCM Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ICCM has a market cap of 347.8M. Regarding current trading prices, BIO-B is priced at $321.48, while ICCM trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ICCM's P/E ratio is -21.54. In terms of profitability, BIO-B's ROE is +0.02%, compared to ICCM's ROE of -2.12%. Regarding short-term risk, BIO-B is less volatile compared to ICCM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ICCM's competition here
BIO-B vs MASS Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, MASS has a market cap of 333.5M. Regarding current trading prices, BIO-B is priced at $321.48, while MASS trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas MASS's P/E ratio is -9.09. In terms of profitability, BIO-B's ROE is +0.02%, compared to MASS's ROE of -0.26%. Regarding short-term risk, BIO-B is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MASS's competition here
BIO-B vs SMLR Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BIO-B is priced at $321.48, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BIO-B's ROE is +0.02%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, BIO-B is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check SMLR's competition here
BIO-B vs ELMD Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ELMD has a market cap of 305.3M. Regarding current trading prices, BIO-B is priced at $321.48, while ELMD trades at $37.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ELMD's P/E ratio is 31.51. In terms of profitability, BIO-B's ROE is +0.02%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, BIO-B is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ELMD's competition here
BIO-B vs SENS Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SENS has a market cap of 292.8M. Regarding current trading prices, BIO-B is priced at $321.48, while SENS trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SENS's P/E ratio is -3.56. In terms of profitability, BIO-B's ROE is +0.02%, compared to SENS's ROE of -1.30%. Regarding short-term risk, BIO-B is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SENS's competition here
BIO-B vs CATX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CATX has a market cap of 250.3M. Regarding current trading prices, BIO-B is priced at $321.48, while CATX trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CATX's P/E ratio is -2.30. In terms of profitability, BIO-B's ROE is +0.02%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BIO-B is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CATX's competition here
BIO-B vs SGHT Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SGHT has a market cap of 250.3M. Regarding current trading prices, BIO-B is priced at $321.48, while SGHT trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SGHT's P/E ratio is -6.57. In terms of profitability, BIO-B's ROE is +0.02%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, BIO-B is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SGHT's competition here
BIO-B vs MGRM Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BIO-B is priced at $321.48, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas MGRM's P/E ratio is -11.11. In terms of profitability, BIO-B's ROE is +0.02%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, BIO-B is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check MGRM's competition here
BIO-B vs TMCI Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, TMCI has a market cap of 239.4M. Regarding current trading prices, BIO-B is priced at $321.48, while TMCI trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas TMCI's P/E ratio is -3.84. In terms of profitability, BIO-B's ROE is +0.02%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, BIO-B is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TMCI's competition here
BIO-B vs NVRO Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIO-B is priced at $321.48, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIO-B's ROE is +0.02%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BIO-B is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check NVRO's competition here
BIO-B vs RXST Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, RXST has a market cap of 211.1M. Regarding current trading prices, BIO-B is priced at $321.48, while RXST trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas RXST's P/E ratio is -4.51. In terms of profitability, BIO-B's ROE is +0.02%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BIO-B is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check RXST's competition here
BIO-B vs EYES Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, BIO-B is priced at $321.48, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas EYES's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.02%, compared to EYES's ROE of -2.64%. Regarding short-term risk, BIO-B is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check EYES's competition here
BIO-B vs PROF Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, PROF has a market cap of 205.8M. Regarding current trading prices, BIO-B is priced at $321.48, while PROF trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas PROF's P/E ratio is -5.48. In terms of profitability, BIO-B's ROE is +0.02%, compared to PROF's ROE of -0.71%. Regarding short-term risk, BIO-B is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PROF's competition here
BIO-B vs ANIK Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, ANIK has a market cap of 196.8M. Regarding current trading prices, BIO-B is priced at $321.48, while ANIK trades at $14.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas ANIK's P/E ratio is -18.72. In terms of profitability, BIO-B's ROE is +0.02%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, BIO-B is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ANIK's competition here
BIO-B vs BSGM Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BIO-B is priced at $321.48, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BIO-B's ROE is +0.02%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, BIO-B is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSGM's competition here
BIO-B vs APYX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, APYX has a market cap of 179.6M. Regarding current trading prices, BIO-B is priced at $321.48, while APYX trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas APYX's P/E ratio is -19.50. In terms of profitability, BIO-B's ROE is +0.02%, compared to APYX's ROE of -0.91%. Regarding short-term risk, BIO-B is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check APYX's competition here
BIO-B vs QTRX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, QTRX has a market cap of 179M. Regarding current trading prices, BIO-B is priced at $321.48, while QTRX trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas QTRX's P/E ratio is -1.62. In terms of profitability, BIO-B's ROE is +0.02%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, BIO-B is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check QTRX's competition here
BIO-B vs MDGS Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BIO-B is priced at $321.48, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BIO-B's ROE is +0.02%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BIO-B is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MDGS's competition here
BIO-B vs EDAP Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, BIO-B is priced at $321.48, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas EDAP's P/E ratio is -5.80. In terms of profitability, BIO-B's ROE is +0.02%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, BIO-B is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check EDAP's competition here
BIO-B vs INGN Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, INGN has a market cap of 170.8M. Regarding current trading prices, BIO-B is priced at $321.48, while INGN trades at $6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas INGN's P/E ratio is -6.93. In terms of profitability, BIO-B's ROE is +0.02%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BIO-B is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check INGN's competition here
BIO-B vs QIPT Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BIO-B is priced at $321.48, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BIO-B's ROE is +0.02%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BIO-B is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check QIPT's competition here
BIO-B vs CVRX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, CVRX has a market cap of 156M. Regarding current trading prices, BIO-B is priced at $321.48, while CVRX trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas CVRX's P/E ratio is -2.93. In terms of profitability, BIO-B's ROE is +0.02%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, BIO-B is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CVRX's competition here
BIO-B vs NNOX Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, NNOX has a market cap of 144.1M. Regarding current trading prices, BIO-B is priced at $321.48, while NNOX trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas NNOX's P/E ratio is -1.78. In terms of profitability, BIO-B's ROE is +0.02%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, BIO-B is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NNOX's competition here
BIO-B vs SNWV Comparison June 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 8.7B. In comparison, SNWV has a market cap of 135M. Regarding current trading prices, BIO-B is priced at $321.48, while SNWV trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 53.40, whereas SNWV's P/E ratio is 16.35. In terms of profitability, BIO-B's ROE is +0.02%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, BIO-B is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SNWV's competition here